US medical devices industry saw a rise of 4.60% in overall deal activity during April 2021, when compared with the last 12-month average, led by $5bn merger of CA Healthcare Acquisition and LumiraDx, according to GlobalData’s deals database.
Go deeper with GlobalData
- Embed this chart
Embed this chart into your website
Copy and paste the image source into your website to display the chart.
A total of 91 deals worth $9.6bn were announced in April 2021, compared with the 12-month average of 87 deals.
venture financing was the leading category in the month in terms of volume with 56 deals, which accounted for 61.5% of all deals.
In second place was M&A with 23 deals, followed by private equity with 12 transactions, respectively accounting for 25.3% and 13.2% of overall deal activity in the US technology industry during the month.
In terms of value of deals, M&A was the leading deal category in the US medical devices industry with total deals worth $7.41bn, while venture financing and private equity deals totalled $1.42bn and $727.8m respectively.
US medical devices industry deals in April 2021: Top deals
The top five medical devices industry deals accounted for 79.8% of the overall value during April 2021.
The combined value of the top five medical devices deals stood at $7.62bn, against the overall value of $9.6bn recorded for the month.
The top five medical devices industry deals of April 2021 tracked by GlobalData were:
1) The $5bn merger of CA Healthcare Acquisition and LumiraDx
2) The $1.8bn acquisition of Luminex by DiaSorin
3) The Carlyle Group’s $435m private equity deal with Unchained Labs
4) The $200m acquisition deal with Genosity by InVitae
5) Mountain Crest AcquisitionII’s acquisition of Better Therapeutics for $187m.
